Browsing by Author "Guiu, Marc"

Sort by: Order: Results:

  • Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.
    Pavlovic, Milica, 1985-; Arnal-Estapé, Anna ; Rojo, Federico; Bellmunt, Anna ; Tarragona, Maria ; Guiu, Marc; Planet, Evarist; Garcia-Albéniz, Xabier; Morales, Mònica; Urosevic, Jelena ; Gawrzak, Sylwia ; Rovira Guerín, Ana; Prat, Aleix; Nonell Mazelon, Lara, 1972-; Lluch, Ana; Jean-Mairet, Joël ; Coleman, Robert ; Albanell Mestres, Joan; Gomis, Roger R. (Oxford Open , 2015)
    BACKGROUND: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest. METHODS: A de novo unbiased ...
  • FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth.
    Slebe Concha, Juan Felipe, 1981-; Rojo, Federico; Vinaixa, Maria; García-Rocha, Mar; Testoni, Giorgia; Guiu, Marc; Planet, Evarist; Samino, Sara; Arenas, Enrique J.; Beltran Marqués, Antoni; Rovira Guerín, Ana; Lluch, Ana; Salvatella, Xavier; Yanes, Oscar; Albanell Mestres, Joan; Guinovart, Joan J. (Joan Josep), 1947-; Gomis, Roger R. (Nature Publishing Group, 2016)
    The mechanisms that allow breast cancer (BCa) cells to metabolically sustain rapid growth are poorly understood. Here we report that BCa cells are dependent on a mechanism to supply precursors for intracellular lipid ...
  • Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
    Rivas, Elisa; Linares Aceituno, Jenniffer Lissethe; Zwick, Melissa; Gómez-Llonín, Andrea; Guiu, Marc; Labernadie, Anna; Badia-Ramentol, Jordi; Lladó, Anna; Bardia, Lídia; Pérez-Núñez, Iván; Martínez-Ciarpaglini, Carolina; Tarazona, Noelia; Sallent-Aragay, Anna; Garrido, Marta; Celià-Terrassa, Toni; Burgués, Octavio; Gomis, Roger R.; Albanell Mestres, Joan; Calon, Alexandre (Nature Research, 2022)
    About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct a detailed analysis of two ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking